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Abstract 
Background: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophos‑
phohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently 
observed among hepatitis C virus (HCV)‑infected patients receiving ribavirin (RBV)‑based therapy. We performed a 
meta‑analysis of all eligible studies assessing ITPA gene polymorphisms related to RBV‑induced hemolytic anemia in 
HCV‑infected patients published in PubMed, Embase and the Cochrane library prior to the end of 2014.
Methods: Three outcomes were evaluated: (1) hemoglobin decline, (2) severe anemia, and (3) RBV dose reduction 
or treatment discontinuation. Pooled odds ratio (OR) and 95 % confidence interval (95 % CI) were estimated by either 
fixed or random effects models.
Results: Twenty‑nine studies were selected from the literature search: 20 references involving 6533 individuals for 
hemoglobin decline, 13 references on 3764 patients for severe anemia, and 16 references on 3918 patients for RBV 
dose reduction or discontinuation. Significant associations with hemoglobin decline were found for rs1127354 CC 
[OR = 12.84 (95 % CI 7.44; 22.17)], rs7270101 AA [OR = 3.41 (95 % CI 2.08; 5.59)] and rs6051702 AA [OR = 4.43 (95 % 
CI 2.80; 7.00)] genotypes. Moreover, significant associations with hemoglobin decline were also found for absent 
[OR = 6.01 (95 % CI 4.84; 7.46)] and mild [OR = 4.68 (95 % CI 2.83; 7.74)] ITPase deficiency haplotypes. The ITPA 
rs1127354 CC genotype and absent ITPase deficiency haplotype were also associated with severe anemia {[OR = 7.77 
(95 % CI 5.03; 12.00)] and [OR = 4.79 (95 % CI 1.69; 13.56)], respectively}. Additionally, the rs1127354 CC genotype 
showed significant association with RBV dose reduction or stopping treatment (OR = 2.24; 95 % CI 1.79; 2.81).
Conclusions: ITPA polymorphisms increase the likelihood of developing hemolytic anemia for HCV‑infected patients 
on RBV‑based therapy, particularly rs1127354 CC and rs7270101 AA genotypes, suggesting the utility of screening for 
ITPA polymorphisms to avoid hematological toxicity and increase adherence to RBV‑based therapy.
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Background
For many years, pegylated interferon-alpha (pegIFNα) 
plus ribavirin (RBV) combination therapy has been the 
standard treatment for hepatitis C virus (HCV) infection, 
but the side-effects have made the therapy arduous for 
many patients [1]. Recently, new direct-acting antivirals 
(DAAs) have improved the response rate, particularly in 
difficult-to-treat patients infected with HCV genotypes 
(GT) 1 or 4, and have made adverse effects less com-
mon [2, 3]. Nevertheless, due to the high cost of DAAs, 
only patients with advanced liver disease will be ini-
tially treated with DAAs according to the new guideline 
[4]. Moreover, pegIFNα/RBV therapy remains an effec-
tive antiviral treatment option for patients infected with 
GT2 and GT3, and its relatively low cost is an advantage. 
Furthermore, the use of triple therapy with pegIFNα/
RBV and DAAs (e.g. simeprevir, sofosbuvir) is still rec-
ommended as well as the use of DAAs with RBV only in 
certain subgroups of patients [2–4]. Thus, RBV continues 
to maintain an important role in HCV therapy even with 
the introduction of DAAs [2–4].
Hemolytic anemia is a common side-effect in HCV-
infected patients on pegIFNα/RBV therapy, affecting 
up to 30 % of patients, which requires close monitoring 
of hemoglobin and dose modification in up to 15  % of 
patients [5]. RBV-induced anemia primarily results in the 
reduction of adenosin triphosphate (ATP) levels in eryth-
rocytes, affecting ATP-dependent oxidative metabolism 
[6, 7]. Genetic variations in the inosine triphosphatase 
(ITPA) gene, which encodes an inosine triphosphate 
pyrophosphohydrolase (ITPase), are associated with pro-
tection from hemolytic anemia during pegIFNα/RBV 
therapy [8]. These ITPA variants affect ITPase function-
ality, causing a drop in its activity, resulting in an accu-
mulation of inosine triphosphate (ITP) in erythrocytes 
and the prevention of oxidative stress [6, 9].
Initially, two ITPA variants (rs1127354 and rs7270101) 
were found to be associated with protection against 
hemolytic anemia during pegIFNα/RBV therapy [8, 
10]. Single nucleotide polymorphisms (SNPs) at both 
of these locations result in functional variants that code 
for a missense mutation in exon 2 (rs1127354, P32T) or 
alter a splice site (rs7270101) [11, 12]. Homozygosity for 
these ITPA minor alleles leads to ITPase deficiency and 
a strong accumulation of ITP in erythrocytes, which is 
associated with lower RBV-toxicity. The ITPA rs6051702 
C minor allele, a more common variant, has also been 
associated with protection from anemia [8].
In recent years, a large number of articles about 
ITPA polymorphisms and RBV-induced anemia have 
been published, although conflicting results have been 
reported. For that reason, our aim was to carefully ana-
lyze the relationship between ITPA polymorphisms and 
hemolytic anemia in HCV-infected patients on RBV-
based HCV therapy by conducting a meta-analysis of all 
eligible studies published to date (December 31, 2014).
Methods
Search strategy and study selection
Relevant studies were identified by searching Pub-
med, Embase and the Cochrane Library from inception 
through December 31, 2014; using the following terms: 
(“hepatitis C” or “HCV” or “chronic hepatitis C”), (“ITPA” 
or “inosine triphosphatase”) (“SNP” or “polymorphism”). 
No language restrictions were applied. The meta-analysis 
was conducted following guidelines from Sutton et  al. 
[13], and the data were reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [14].
We applied strict inclusion and exclusion criteria 
before reviewing the studies and extracting the data:
(a)   Inclusion criteria (1) patients infected with HCV or 
HCV/human immunodeficiency virus (HIV) coin-
fection; (2) any SNP located within or near the ITPA 
gene (described in two or more articles); (3) HCV 
treatment-based RBV alone or in combination with 
pegIFNα (2a or 2b) (combined or not with DAAs); 
(4) available data on at least one outcome.
(b)  Exclusion criteria (1) coinfection with hepatitis B 
virus; (2) treatment duration of less than 12  weeks 
or no treatment; (3) absent or inadequate informa-
tion about treatment, study population, HCV sta-
tus, or not enough information to calculate the odds 
ratio (OR) and 95 % confidence intervals (95 % CI); 
(4) studies with sample size less than 40 subjects; 
(5) reviews, editorials, letters, chapters, conference 
abstracts or clinical case reports.
In order to select the candidate studies, we screened 
the title and abstract of each publication. When arti-
cles fulfilled the inclusion criteria, we examined the full 
text and extracted data from the study. When studies 
included several subgroups and some of them did not 
fulfil the inclusion criteria, we only incorporated into the 
meta-analysis those subgroups that did meet the inclu-
sion criteria. When more than one article studying the 
same cohort was found, only the study with the most 
extensive cohort was reviewed, excluding the remaining 
overlapping studies or data.
Two authors (DPT and MGA) performed the literature 
search and the study selection separately.
Data extraction
Data were extracted independently by two investigators 
(DPT and MGA) and then cross-checked. When data were 
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unclear or required assumptions to be made, other investi-
gators (MAJS and SR) were consulted so that a consensus 
could be reached before recording an entry in the database. 
Authors of included studies were contacted when the data 
were not explicitly reported or any clarification was needed.
Outcome variables
Three outcome variables were evaluated: (1) Hemoglobin 
decline a decrease in hemoglobin of more than 2 or 3 g/
dL [8, 10, 15–32]; (2) Severe anemia hemoglobin levels 
less than 8.5, 8.9, 10 or 10.5 g/dL [8, 18, 20, 23, 24, 26, 27, 
30–35]; (3) Ribavirin dose reduction or discontinuation of 
treatment that resulted from significant anemia defined 
by several cut-offs (8.5, 10 or 12 g/dL) or physician’s crite-
ria [10, 15–18, 22, 27, 30, 34–41].
ITPA polymorphisms
The following ITPA polymorphisms and haplotypes were 
included in the analyses:
1. rs1127354 (C>A): missense variant in exon 2 result-
ing in a proline-to-threonine substitution (P32T) [8]. 
NCBI SNP database: http://www.ncbi.nlm.nih.gov/
projects/SNP/snp_ref.cgi?rs=1127354.
2. rs7270101 (A>C): splice-altering SNP located in 
the second intron [8]. NCBI SNP database: http://
www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?rs=7270101.
3. rs6051702 (A>C): non-functional variant localized 
in a non-coding region adjacent to the ITPA gene 
(20p13) [8]. NCBI SNP database: http://www.ncbi.
nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6051702.
4. rs1127354/rs7270101 haplotype: ITPase deficiency 
ranging from absent (−) (representing wild-type 
activity) to mild (+), moderate (++) or severe 
(+++) (Additional file 1: Box 1) [8, 10].
The SNPs studied were in agreement with Hardy–
Weinberg equilibrium (p  >  0.05), estimated by the Chi 
squared test.
Quality assessment
Two investigators (MGA and DPT) independently evalu-
ated the study quality using an evaluation system modified 
from the Newcastle–Ottawa Scale. A description of the 
adapted methodological quality criteria is available in Addi-
tional file 1: Box 2. The full score was 20 stars, and a high-
quality study was defined as a study with 15 or more stars.
Statistical analysis
All analyses were performed using Stata software (ver-
sion 11.0; Stata Corporation, College Station, TX, USA). 
All p values <0.05 were considered significant.
Overall, meta-analysis was performed only when two 
or more articles studying the same outcome were avail-
able. In all analyses, pooled OR and 95 % CI were calcu-
lated. The significance of the pooled OR was calculated 
by the Z test. The study heterogeneity was assessed using 
the Cochran’s Q statistic and I2 statistic, considering a 
Q statistic p < 0.1 or I2 > 50 % as significant heterogene-
ity. A fixed effect model (a traditional Mantel–Haenszel 
method) was used for homogeneous studies. When sig-
nificant heterogeneity existed, a random effect model 
was applied (DerSimonian and Laird method) and a 
Galbraith plot was used to detect possible outliers of 
the heterogeneity. In addition, when heterogeneity was 
detected, meta-regression analysis was also performed 
with the aim of defining the potential effect of the covari-
ates on the outcome variables. The regression coefficients 
obtained describe how the hemoglobin decline, severe 
anemia or ribavirin dose reduction changed with each 
unit increase in the covariate. Significance of the linear 
relationship was identified by the p value. The covari-
ates analyzed were: cut-off, time of analysis, sex, age, 
racial descent, HCV-genotype, HCV therapy and HIV 
coinfection.
Publication bias was assessed by Begg’s funnel plot and 
the Egger linear regression test which detects funnel plot 
asymmetry. Publication bias was assumed to exist when 
the Egger test reported a p < 0.05. The sensitivity analyses 
were also conducted to assess the consistency of results 
and to investigate the influence of one study on the over-
all meta-analysis. It was carried out by sequential omis-
sion of individual studies.
Results
Search results
The search strategy yielded 61 entries, 42 of which were 
considered to have potential value and the full texts were 
retrieved for detailed evaluation (Fig. 1). After exclusion 
based on detailed assessment, 29 studies were eligible for 
inclusion (20 for hemoglobin decline, 13 for severe ane-
mia and 16 for RBV dose reduction or discontinuation 
of treatment meta-analysis). Seventeen of the 29 studies 
were included in more than one analysis.
Article characteristics
The main characteristics of the included studies from 
2010 to 2014 are summarized in Table 1: 533 individuals 
for hemoglobin decline, 3764 patients for severe anemia, 
and 3918 patients for RBV dose reduction or discontinua-
tion of treatment. Data were collected from several coun-
tries with different ethnicities and HCV genotypes. Five 
references included HCV/HIV-coinfected patients, and 
three studies included HCV therapy based in PegIFN/
RBV plus telaprevir. The specific characteristics for each 
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outcome are showed in Table  2. Several cut-offs for the 
outcome definition were employed and various times of 
analysis were used.
Quality assessment
The quality scores of the studies included are summa-
rized in Additional file  1: Table S1. The scores ranged 
from 9 to 18, with a mean value of 14 ± 1.98.
Publication bias
The SNPs and haplotypes found in more than 10 arti-
cles were evaluated for publication bias tests. Analysis 
of publication bias was only necessary for rs1127354 in 
hemoglobin decline (Additional file 1: Figure S1A), severe 
anemia (Additional file  1: Figure S1B) and RBV dose 
reduction or discontinuation of treatment (Additional 
file  1: Figure S1C) meta-analyses. Nevertheless, the 
Egger’s test indicated that there was publication bias for 
rs1127354 (p = 0.019) in severe anemia meta-analysis.
ITPA polymorphisms and hemoglobin decline
A total of 20 references examined the association 
between ITPA polymorphisms and hemoglobin decline 
(Fig. 2).
The data for rs1127354 CC vs. CA/AA are shown in 
Fig. 2a. From 14 studies analyzed, 11 of them showed a 
significant association between rs1127354 CC geno-
type and hemoglobin decline. The pooled OR was 12.84 
(95 % CI 7.44; 22.17), but a strong heterogeneity among 
the studies was found (I2 = 61.4 %; p = 0.001) (Fig. 2a). 
When the Galbraith plot was used, three outlier studies 
were identified: Sakamoto et al. [15], Azakami et al. [17], 
Fig. 1 Flowchart showing the selection of articles included in the meta‑analysis. Asterisk several studies were eligible for different categories
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Table 1 General characteristics of studies included in our meta-analysis for hemoglobin decline, severe anemia and riba-
virin dose reduction or discontinuation
A asians, AA africans ascendence, C caucasians, H hispanics, Hb hemoglobin, NR not reported, Peg-IFN pegilated inferferon, RBV ribavirin, TPV telaprevir










2010 Fellay [8] GWAS 1286 47.3 61.74 USA C (76.8), H (7.8), 
AA (15.4)
1 100 Peg‑ + RBV No
2010 Thompson 
[10]
GWAS 318 48.5 65 USA C (55), AA (45) 1 100 Peg‑α2a + RBV No
2010 Sakamoto [15] Cross‑sec‑
tional





238 52 59 Italy, USA C (100) 2, 3 0 Peg‑α2b + RBV No
2011 Azakami [17] Retrospec‑
tive
1002 58 53.9 Japan A (100) 1, Others NR Peg‑α2b + RBV No
2011 Chayama [36] NR 94 57 55.3 Japan A (100) 1 100 Peg‑α2b + RBV + TPV No
2011 Kurosaki [18] Retrospec‑
tive
132 57.5 37.9 Japan A (100) 1b 100 Peg‑α2a/2b + RBV No
2011 Rallón [19] Retrospec‑
tive
74 43 74 Spain NR 1, 2, 3, 4 87 Peg‑α2a/2b + RBV Yes (NR)
2012 Nishimura 
[20]
NR 176 62 61.5 Japan A (100) 1, 2 NR Peg‑α2a/2b + RBV No
2012 Naggie [21] Retrospec‑
tive
161 42 75 Spain C (100) 1, 2, 3, 4 70 Peg‑α2a/2b + RBV Yes (84)
2012 Domingo [22] Prospective 73 46.8 58.9 Spain NR 1, 3, 4 75.3 Peg‑α2a + RBV Yes (91.8)
2012 Osinusi [23] NR 123 45.5 70.7 Germany, 
USA
C (58.5), AA 
(30.9), other 
(10.6)
1, 2, 3 NR Peg‑α2a/2b + RBV Yes (83.1)
2012 Miyamura [37] Retrospec‑
tive
97 55.8 45.36 Japan A (100) 1, 2 NR Peg‑α2a + RBV No
2012 Vidal [33] Prospective 113 40 74.3 Spain NR 1, 2, 3, 4 61.6 Peg‑α2a/2b + RBV Yes (84.1)
2012 Tsubota [24] Prospective 561 59.1 53.8 Japan A (100) 1b 100 Peg‑α2a/2b + RBV No
2013 Rau [25] Retrospec‑
tive
216 NR 64.8 Switzer‑
land
C (100) 1, 2, 3 NR Peg‑α + RBV No
2013 Di Marco [26] Prospective 233 58.7 64 Italy NR 1, 2, 3 NR Peg‑α2b + RBV No
2013 Ahmed [27] Retrospec‑
tive
102 32.5 88.2 Egypt C (100) 1, 4 100 Peg‑α2a/2b + RBV No
2013 Ogawa [34] Prospective 292 62 46.2 Japan A (100) 1 100 Peg‑α2b + RBV + TPV No
2013 Scherzer [28] Retrospec‑
tive
308 43.9 60.1 Austria C (100) 1 100 Peg‑α2a + RBV No
2013 Fujino [38] Retrospec‑
tive
120 NR 45.8 Japan A (100) 1b 100 Peg‑α2a/2b + RBV No
2013 D’Avolio [29] Retrospec‑
tive
379 46 60.9 Italy C (94.9), AA (5.1) 1, 2, 3, 4 56.2 Peg‑α2a/2b + RBV No
2013 Clark [30] Prospective 193 NR 56.5 Italy NR 1, 2, 3, 4 63.73 Peg‑α2a + RBV No
2013 Seto [39] NR 60 49 68.3 Hong 
Kong





300 57 51 Japan A (100) 1, 2 NR Peg‑ + RBV No
2014 Matsuura [31] NR 309 57 52 Japan A (100) 1 100 Peg‑α2a/2b + RBV No
2014 Rembeck [41] Retrospec‑
tive
354 42 42 Scandina‑
vian
C (100) 2, 3 0 Peg‑α2a + RBV No
2014 Aghemo [35] Retrospec‑
tive
69 57 67 Italy NR 1 100 Peg‑
α2a/2b + RBV + TPV
No
2014 Hwang [32] Cross‑sec‑
tional
175 55.5 66.3 Taiwan NR 1, others 63.4 Peg‑α2a/2b + RBV No
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and Matsuura et al. [31] (Additional file 1: Figure S2A). A 
forest plot omitting these outliers was constructed, which 
reduced the heterogeneity (I2 = 39.9 %), but the pooled 
OR was not altered [OR = 12.35 (95 % CI 6.62; 23.04)]. 
The sensitivity analysis showed that no study should be 
excluded (Additional file 1: Figure S3A).
The data for rs7270101 AA vs. AC/CC are shown in 
Fig. 2b. From 5 studies analyzed, 4 of them showed a sig-
nificant association between rs7270101 AA genotype and 
hemoglobin decline. The pooled OR was 3.41 (95  % CI 
2.08; 5.59), but a strong heterogeneity among the studies 
was found (I2 =  65.4 %; p =  0.021) (Fig. 2b). When the 
Table 2 Specific characteristics of  included studies for  hemoglobin decline (A), severe anemia (B) and  ribavirin dose 
reduction or discontinuation (C)
Hb hemoglobin, NR not reported
Year First author ITPA  
Polymorphism
(A) Hemoglobin decline (B) Severe anemia (C) Ribavirin dose reduction 
or stop treatment
Cut-off Hb Time of analysis Cut-off Hb Time of analysis Cut-off Hb Time of analysis
2010 Fellay [8] rs1127354
rs7270101
Haplotype
>3 g/dL 4 weeks <10 g/dL 4 weeks NR NR
2010 Thompson [10] Haplotype >3 g/dL 4 weeks NR NR <8.5 g/dL During treatment
2010 Sakamoto [15] rs1127354 >3 g/dL 4 weeks NR NR 8.5–10 g/dL 4 weeks
2011 Thompson [16] Haplotype >3 g/dL 4/12/24 weeks NR NR <9.5 g/dL During treatment
2011 Azakami [17] rs1127354 >2 g/dL 4 weeks NR NR <8.5 g/dL During treatment
2011 Chayama [36] rs1127354 NR NR NR NR <12 g/dL 12 weeks
2011 Kurosaki [18] rs1127354 >3 g/dL 4 weeks
During treatment
<10 g/dL 4 weeks
During treatment
NR During treatment
2011 Rallón [19] rs1127354
rs7270101
Haplotype
>2 g/dL 4 weeks NR NR NR NR
2012 Nishimura [20] rs1127354 >3 g/dL 4 weeks <10 g/dL 4 weeks NR NR
2012 Naggie [21] Haplotype >3 g/dL 4 weeks NR NR NR NR
2012 Domingo [22] rs1127354 >3 g/dL 4 weeks NR NR NR During treatment
2012 Osinusi [23] Haplotype >3 g/dL 4 weeks <10 g/dL 4 weeks NR NR
2012 Miyamura [37] rs1127354 NR NR NR NR NR 4 weeks
2012 Vidal [33] rs1127354 NR NR <10.5 g/dL During treatment NR NR
2012 Tsubota [24] rs1127354 >3 g/dL 4 weeks <10 g/dL 4 weeks NR NR
2013 Rau [25] rs1127354
rs7270101
Haplotype
>3 g/dL During treatment NR NR NR NR
2013 Di Marco [26] Haplotype >3 g/dL 4 weeks <10 g/dL During treatment NR NR
2013 Ahmed [27] rs1127354 >3 g/dL 4 weeks <10 g/dL 12 weeks NR 12 weeks
2013 Ogawa [34] rs1127354 NR NR <8.5 g/dL During treatment NR 8–16 weeks
2013 Scherzer [28] rs1127354
rs7270101
rs6051702
>3 g/dL 4 weeks NR NR NR NR
2013 Fujino [38] rs1127354 NR NR NR NR NR During treatment
2013 D’Avolio [29] rs1127354
rs7270101
rs6051702
>3 g/dL 4 weeks NR NR NR NR
2013 Clark [30] Haplotype >3 g/dL 4 weeks <10 g/dL 4 weeks 8.5–10 g/dL During treatment
2013 Seto [39] rs1127354 NR NR NR NR 8.5–10 g/dL During treatment
2013 Nakagawa [40] rs1127354 NR NR NR NR NR 4 weeks
2014 Matsuura [31] rs1127354 >3 g/dL 12 weeks <10 g/dL 12 weeks NR NR
2014 Rembeck [41] Haplotype NR NR NR NR NR During treatment
2014 Aghemo [35] Haplotype NR NR <8.9 g/dL During treatment 8.5–10 g/dL During treatment
2014 Hwang [32] rs1127354
rs6051702
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Fig. 2 Forest plot shows the association between ITPA polymorphisms and hemoglobin decline. CI confidence intervals, OR odds ratio
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Galbraith plot was used, one outlier of heterogeneity was 
identified: Fellay et al. [8] (Additional file 1: Figure S2B). 
When the mentioned outlier was deleted, a reduced het-
erogeneity was observed (I2 = 17.0 %), but the pooled OR 
was not altered [OR = 2.70 (95 % CI 1.78; 4.10)]. The sen-
sitivity analysis showed that no study should be excluded 
(Additional file 1: Figure S3B).
The data for rs6051702 AA vs. AC/CC are shown in 
Additional file  1: Figure S4 and Fig.  2c. From 3 stud-
ies analyzed, 2 of them showed a significant associa-
tion between rs6051702 AA genotype and hemoglobin 
decline. Nevertheless, the pooled OR was not significant 
[OR =  2.16 (95  % CI 0.54; 8.63)], but a strong hetero-
geneity was found among them (I2 = 92.4 %; p < 0.001) 
(Additional file 1: Figure S4). In this case, Galbraith´s plot 
identified one outlier as a source of heterogeneity: Hwang 
et al. [32] (Additional file 1: Figure S2C). Using sensitiv-
ity analysis (Additional file 1: Figure S3C) we found that 
the data from Hwang et al. [32] apparently influenced the 
overall results. Based on these issues, we considered the 
exclusion of this article from the analysis to be justified. 
When the meta-analysis was performed excluding this 
outlier, the heterogeneity disappeared (I2 =  0.0  %) and 
the pooled OR was significant [OR = 4.43 (95 % CI 2.80; 
7.00)] (Fig. 2c). In any case, this analysis had a very small 
number of studies and the pooled OR should be consid-
ered with this taken into account.
ITPA haplotypes related to ITPase deficiency [8, 10] 
were also analysed.
The data for absent (−) vs. mild (+)/moderate (++)/
severe (+++) ITPase deficiency are shown in Fig. 2d. All 
studies showed a significant association between absent 
(−) ITPase deficiency haplotype and hemoglobin decline. 
The pooled OR was 6.01 (95 % CI 4.84; 7.46). There was 
no significant heterogeneity among studies (I2 = 30.4 %; 
p = 0.176) (Fig. 2d). The sensitivity analysis showed that 
no study should be excluded (Additional file  1: Figure 
S3D).
The data for mild (+) vs. moderate (++)/severe (+++) 
ITPase deficiency are shown in Fig.  2e. From 8 stud-
ies analyzed, 3 of them showed a significant associa-
tion between mild (+) ITPase deficiency haplotype and 
hemoglobin decline. The pooled OR was 4.68 (95  % CI 
2.83; 7.74). There was no significant heterogeneity among 
studies (I2 =  5.7  %; p =  0.386) (Fig.  2e). The sensitivity 
analysis showed that no study should be excluded (Addi-
tional file 1: Figure S3E).
The data for moderate (++) vs. severe (+++) ITPase 
deficiency are shown in Fig. 2f. From 4 studies analyzed, 
none showed a significant association between moder-
ate (++) ITPase deficiency and hemoglobin decline. The 
pooled OR was not significant [OR = 1.84 (95 % CI 0.39; 
8.69)]. There was no significant heterogeneity among 
studies (I2 =  0.0  %; p =  0.819) (Fig.  2f ). The sensitivity 
analysis showed that no study should be excluded (Addi-
tional file 1: Figure S3F).
ITPA polymorphisms and severe anemia
A total of 13 references were examined to evaluate the 
association between ITPA polymorphisms and severe 
anemia (Fig.  3). We were able to perform the analysis 
only for the ITPA rs1127354 polymorphism and two 
haplotypes that predict the deficiency of ITPase activity 
(absent and mild).
The data for rs1127354 CC vs. CA/AA are shown in 
Fig.  3a. From 10 studies analyzed, 7 of them showed a 
significant association between rs1127354 CC geno-
type and severe anemia. The pooled OR was 7.77 (95 % 
CI 5.03; 12.00). There was no significant heterogeneity 
among studies (I2 = 32.7 %; p = 0.146) (Fig. 3a). The sen-
sitivity analysis showed that no study should be excluded 
(Additional file 1: Figure S5A).
The data for absent (−) vs. mild (+)/moderate (++)/
severe (+++) ITPase deficiency are shown in Fig.  3b. 
From 5 studies analyzed, 3 showed a significant associa-
tion between absent (−) ITPase deficiency haplotype and 
severe anemia. The pooled OR was 4.79 (95  % CI 1.69; 
13.56), but a strong heterogeneity among the studies was 
found (I2 = 75.5 %; p = 0.003) (Fig. 3b). When the Gal-
braith plot was used, one outlier study was identified: 
Fellay et al. [8] (Additional file 1: Figure S2D). When the 
meta-analysis was performed excluding this outlier, the 
heterogeneity disappeared (I2 =  0.0  %), and the pooled 
OR decreased [OR = 2.80 (95 % CI 1.74; 4.51)]. The sen-
sitivity analysis showed that no study should be excluded 
(Additional file 1: Figure S5B).
The data for mild (+) vs. moderate (++)/severe (+++) 
ITPase deficiency are shown in Fig.  3c. From 3 studies 
analyzed, none showed a significant association between 
mild (+) ITPase deficiency and severe anemia. Conse-
quently, the pooled OR was not significant [OR =  2.13 
(95  % CI 0.55; 8.31)]. There was no significant hetero-
geneity among studies (I2 =  0.0  %; p =  0.874) (Fig.  3c). 
The sensitivity analysis showed that no study should be 
excluded (Additional file 1: Figure S5C).
ITPA polymorphisms and ribavirin-dose reduction or stop 
treatment
A total of 16 references were examined to evaluate the 
association between ITPA polymorphisms and RBV dose 
reduction or discontinuation (Fig.  4). We were able to 
perform the analysis only for ITPA rs1127354 and the 
three haplotypes that predict the deficiency of ITPase 
activity.
The data for rs1127354 CC vs. CA/AA are shown in 
Fig.  4a. From 11 studies analyzed, 6 of them showed a 
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significant association between rs1127354 CC genotype 
and RBV dose reduction or discontinuation. The pooled 
OR was 2.24 (95 % CI 1.79; 2.81), but heterogeneity was 
found among the studies (I2 = 45.9 %; p = 0.047) (Fig. 4a). 
When the Galbraith plot was used, one outlier study was 
identified: Kurosaki et  al. [18] (Additional file  1: Figure 
S2E). A forest plot omitting the outlier was constructed, 
which reduced heterogeneity (I2 = 5.0 %; p = 0.394) and 
the pooled OR was not altered [OR = 2.52 (95 % CI 1.98; 
3.20)]. Additionally, the sensitivity analysis showed that 
none of the 11 studies should be omitted from the analy-
sis (Additional file 1: Figure S6A).
The data for absent (−) vs. mild (+)/moderate (++)/
severe (+++) ITPase deficiency are shown in Fig.  4b. 
From 5 studies analyzed, only one showed a significant 
association between absent (−) ITPase deficiency hap-
lotype and RBV dose reduction or discontinuation. The 
pooled OR was not significant [OR = 1.30 (95 % CI 0.73; 
2.31)]. There was no significant heterogeneity among 
studies (I2 = 48.4 %; p = 0.101) (Fig. 4b). The sensitivity 
analysis showed that no study should be excluded (Addi-
tional file 1: Figure S6B).
The data for mild (+) vs. moderate (++)/severe (+++) 
ITPase deficiency are shown in Fig.  4c. From 5 studies 
analyzed, none showed a significant association between 
mild (+) ITPase deficiency and RBV dose reduction or 
discontinuation. Consequently, the pooled OR was not 
significant [OR =  1.74 (95  % CI 0.86; 3.52)]. There was 
no significant heterogeneity among studies (I2 =  0.0  %; 
p = 0.489) (Fig. 4c). The sensitivity analysis showed that 
no study should be excluded (Additional file  1: Figure 
S6C).
The data for moderate (++) vs. severe (+++) ITPase 
deficiency are shown in Fig. 4d. From 3 studies analyzed, 
none showed a significant association between moder-
ate (++) ITPase deficiency and RBV dose reduction or 
discontinuation. Consequently, the pooled OR was not 
significant [OR =  0.82 (95  % CI 0.16; 4.30)]. There was 
not significant heterogeneity among studies (I2 = 0.0 %; 
p = 0.724) (Fig. 4d). The sensitivity analysis showed that 
Fig. 3 Forest plot shows the association between ITPA polymorphisms and severe anemia. CI confidence intervals, OR odds ratio
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no study should be excluded (Additional file  1: Figure 
S6D).
Meta-regression analysis
Several factors were analyzed to investigate the possible 
influence on the heterogeneity (Additional file  1: Table 
S2). However, no significant association between these 
factors and the outcome variables was found (Additional 
file 1: Table S2).
Discussion
The three major results of our meta-analysis were: (1) 
The presence of the major alleles in homozygosis for 
ITPA polymorphisms (rs1127354 CC, rs7270101 AA, 
and rs6051702 AA) was associated with a higher chance 
of developing hemoglobin decline. Additionally, sig-
nificant associations with a higher chance of develop-
ing hemoglobin decline were found both absent (−) and 
mild (+) ITPase deficiency haplotypes. (2) The ITPA 
rs1127354 polymorphism and absent (−) ITPase defi-
ciency haplotype were associated with severe anemia. (3) 
The rs1127354 CC genotype showed a significant asso-
ciation with RBV dose reduction or discontinuation of 
treatment.
Hemolytic anemia is an important side-effect in 
RBV-based HCV therapy [2–4]. The toxicity is RBV 
Fig. 4 Forest plot shows the association between ITPA polymorphisms and ribavirin dose reduction or discontinuation. CI confidence intervals, OR 
odds ratio
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concentration-dependent and anemia improves upon 
dose reduction [5], but high variability limits the pre-
diction of anemia based on RBV plasma concentra-
tions. Clinical risk factors for severe RBV-induced 
anemia include impaired renal function, age, dose per 
body weight, female gender, baseline platelet levels, 
baseline hemoglobin levels, and haptoglobin phenotype 
[42–44]. In this context, the identification of successful 
predictors of RBV-induced anemia is of great value for 
preventing its toxicity.
In our meta-analysis, we found a significant associa-
tion between the unfavorable ITPA genotypes (homozy-
gous major alleles) of the three SNPs studied (rs1127354, 
rs7270101 and rs6051702) and RBV-induced hemolytic 
anemia. In most of the studies, the odds of developing 
anemia was more than double in patients with an unfa-
vorable ITPA genotype than in patients with a protective 
ITPA minor variant. However, the magnitude of the asso-
ciation was different in many cases. This may be due to 
the different criteria considered in each individual study.
Although ITPA polymorphisms have been associated 
with hemoglobin decline, few studies have compared the 
predictive value of combining the three ITPA polymor-
phisms, probably because of the scattered distribution of 
these ITPA polymorphisms among diverse ethnic groups 
and world populations. In our meta-analysis, a simulta-
neous evaluation of the three ITPA SNPs (rs1127354, 
rs7270101 and rs6051702) was done when possible, but 
the rs6051702 polymorphism was rarely encountered and 
often there was too little data to draw robust conclusions 
on all three. The ITPA rs1127354 polymorphism (P32T 
substitution) exists at low frequency in Central and South 
American populations (1–2  %), at a constant frequency 
across Caucasian and African populations (6–7 %), and at 
the highest frequencies in Asian populations (14–19  %) 
[45]. Also, the rs7270101 is known to not be polymorphic 
in the Japanese population [46]. For these reasons, race 
was analyzed in the meta-regression as a covariate, but it 
was not a determinant of heterogeneity in the outcomes 
analyzed. However, we think that this is probably due to 
the preselection of ITPA polymorphisms according to the 
study population.
The decrease in hemoglobin levels was the outcome 
most frequently studied and the only one that pro-
vided enough data to compare the three ITPA polymor-
phisms. There were two studies that showed the three 
SNPs at the same time [28, 29], and our meta-analysis 
was in agreement with them. The rs1127354 polymor-
phism was associated with higher odds of hemoglobin 
reduction, whereas rs7270101 and rs6051702 also 
showed associations in the same direction albeit to a 
lesser degree. The haplotypes related to a higher pre-
dicted ITPase activity, defined by the presence of ITPA 
major alleles at the polymorphic sites rs1127354 and 
rs7270101, also showed a similar trend. Relationships 
in the same direction were found for severe anemia, but 
with fewer studies. However, almost no significant asso-
ciations were found for ITPA polymorphisms or haplo-
types with RBV dose reduction or discontinuation. This 
might be explained by the multiple factors influencing 
this outcome or due to the inclusion of different events 
in the same endpoint (RBV dose reduction and/or dis-
continuation), which are reported at different times 
during treatment. In addition, the need for therapy 
modification may be influenced by other clinical factors 
that were not taken into account. Of special interest is 
the use of erythropoietin (EPO) to improve hemoglobin 
levels and limit the need to reduce the dose of RBV [47]. 
To date, no prospective trials have been performed to 
definitely demonstrate that the use of EPO has a posi-
tive impact on SVR, but EPO is administered in some 
countries when the hemoglobin level falls below 10  g/
dL or by physician criteria. [2, 3]. Despite this, no gen-
eral consensus exists regarding the use of EPO, and it 
is not available to treat this condition everywhere. This 
meta-analysis includes seven studies in which the use of 
EPO was allowed [19, 22, 23, 26, 30, 33, 35], but eryth-
ropoietin was not considered as a covariate because: (1) 
the percentage of patients who received erythropoietin 
was low (3 %) (data not shown); (2) some studies did not 
provide this information or is not detailed; and (3) in 
most cases, the anemia occurred before treatment with 
erythropoietin was administered.
The heterogeneity of the studies must be taken into 
account in a meta-analysis. The covariates from the study 
population that were included in the analysis were age, 
gender and HIV coinfection, which have been previ-
ously described as risk factors for RBV-induced anemia 
[19, 42]. Another cause of heterogeneity is the definitions 
of the clinical endpoints established in each study. Fellay 
et al. [8] were the pioneers in these studies, and the clini-
cal endpoints that they established have been followed 
by other authors. The hemoglobin reduction of 3 g/dL or 
more within 4 weeks of starting treatment is considered 
to be a significant indicator of anemia. The hemoglobin 
value <10 g/dL is the level at which RBV dose reduction 
is recommended, and when hemoglobin is <8.5  g/dL, 
RBV therapy is stopped permanently, according to inter-
national guidelines [2, 3]. However, other authors have 
categorized anemia as mild, moderate or severe accord-
ing to a modification of the World Health Organization 
scale (International Statistical Classification of Diseases 
and Related Health Problems) [33]. The time of analy-
sis is also heterogeneous, since clinical endpoints have 
been reported at 4  weeks, 12  weeks or any time during 
treatment. The time on HCV therapy is an important 
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factor in the development of anemia. Moreover, the 
HCV genotype affects the type and duration of treat-
ment since patients with GT2/3 are prescribed 24-week 
treatments and patients with GT1/4 undergo treatments 
of 48  weeks. Besides, the administered RBV doses are 
adjusted according to HCV genotype and responsiveness 
to treatment. For these reasons, we analyzed these fac-
tors in our meta-analysis, finding that they did not con-
stitute a significant source of heterogeneity.
The severity of RBV-related anemia is known for long 
but it is difficult to assess the role of each drug (RBV, 
pegIFNα or DAAs) in the anemia. Although most of the 
studies have been performed in patients on combined 
therapy (pegIFNα/RBV), a strong association between 
an ITPA SNP and anemia has been reported in patients 
on RBV monotherapy [48]. Moreover, the inclusion of 
DAAs in HCV therapy should be taken into consideration 
when studying anemia in HCV-infected patients, since 
the first generation of protease inhibitors (boceprevir 
and telaprevir) has been found to be associated with an 
increased anemia frequency and severity [49]. Data from 
telaprevir-based triple therapy patients are provided by 
three of the studies included in our meta-analysis [34–36], 
with a frequency of severe anemia over 75  %. However, 
some discrepancies have been detected regarding these 
data. While some authors reported that ITPA rs1127354 
is a useful predictor of the development of severe ane-
mia in telaprevir-based triple therapy patients [34, 36], 
Aghemo et al. reported that an ITPA polymorphism was 
not associated with early anemia or therapy modification 
[35]. These differences may be due to SNPs studied, the 
selected population (all in advanced stages of fibrosis) and 
the limited of sample size. In any case, although no signifi-
cant results were found, the same trend was observed for 
telaprevir-based therapy as in the overall results.
To date, no data have been available about ITPA poly-
morphisms and the second-generation of DAAs, such as 
sofosbuvir, simeprevir, and daclatasvir. Note that patients 
undergoing triple therapy with pegIFN/RBV plus these 
new DAAs have similar anemia frequencies and profiles 
as patients receiving pegIFN/RBV alone [50, 51]. In a 
recent study, 72 % of patients who received simeprevir or 
sofosbuvir plus RBV developed anemia requiring inter-
vention [52]. Thus, ITPA polymorphisms will still be 
useful in preventing anemia while RBV continues to be 
included in HCV treatment regimens.
Finally, in order to properly interpret our results, some 
considerations have to be taken into account. Firstly, our 
meta-analysis was performed by using the unadjusted raw 
data provided from each study, whereas most of the results 
given by the authors had been adjusted by age, gender, 
HCV viral load, and/or other factors. For this reason, the 
pooled ORs may differ slightly from those reported in the 
original articles. Secondly, renal function, baseline hemo-
globin level and other variables involved in determining 
individual susceptibility to RBV-induced anemia have not 
been considered. Thirdly, most studies reported the results 
as haplotype, which does not allow the results of each 
polymorphism to be evaluated separately. Fourthly, the 
majority of the studies had a retrospective design and the 
number of studies in some subgroup analyses was small, 
which might have led to weak results. Consequently, these 
results should be interpreted with caution.
In conclusion, ITPA polymorphisms increase the likeli-
hood of developing hemolytic anemia in HCV-infected 
patients on RBV-based therapy, rs1127354 CC and 
rs7270101 AA genotypes, suggesting the utility of screen-
ing for ITPA polymorphisms as a way to avoid hematologi-
cal toxicity and increase adherence to RBV-based therapy.
Additional file
Additional file 1: Table S1. Methodological quality of the studies 
included in the meta‑analysis, which was assessed using a modified score 
based in the Newcastle–Ottawa Scale (Stang A. Critical evaluation of the 
Newcastle–Ottawa scale for the assessment of the quality of nonrand‑
omized studies in meta‑analyses. Eur J Epidemiol 2010;25:603–605). (see 
Supplemental Box 2). Table S2. Meta‑regression analysis for hemo‑
globin decline (A–C), severe anemia (D) and ribavirin dose reduction or 
discontinuation (E) according to ITPA polymorphisms. Box 1. Description 
of rs1127354/rs7270101 haplotype: ITPase deficiency ranged from absent 
(‑) (representing wild‑type activity) to mild (+), moderate (++) or severe 
(+++) (8, 10). Box 2. Methodological criteria used to evaluate the quality 
of the studies included in the meta‑analysis. This score was adapted from 
Newcastle–Ottawa Scale (Stang A. Critical evaluation of the Newcastle‑
Ottawa scale for the assessment of the quality of nonrandomized studies 
in meta‑analyses. Eur J Epidemiol 2010;25:603–605). Figure S1. Publica‑
tion bias for the rs1127354 studies included in the meta‑analysis for 
hemoglobin decline(A), severe anemia (B) and ribavirin dose reduction or 
discontinuation (C) according both to Begg’s funnel plots and Egger’s test. 
Abbreviations: Coef., asymmetry regression coefficient; Std.Err., standard 
error; t,statistic; P>|t|, significance; and CI, confidence interval. Coefficients 
correspond to the intercept value in the regression equation, which esti‑
mates the asymmetry of the funnel plot. Positive values (Coef.> 0) indicate 
higher levels of effect size in studies with smaller sample sizes. Figure S2. 
Publication heterogeneity for studies included in the meta‑analysis for 
hemoglobin decline: rs1127354 (A), rs7270101 (B), rs6051702 (C); severe 
anemia: haplotype rs1127354CC / rs7270101AA (D); and ribavirin dose 
reduction or discontinuation: rs1127354 (E); according to Galbraith’s plots. 
Abbreviations 1/s.e, precision; b/s.e, standardized effect. Figure S3. Sen‑
sitivity analysis for studies included in the meta‑analysis for hemoglobin 
decline: rs1127354 (A), rs7270101 (B), rs6051702 (C), haplotype absent (‑) 
vs. mild (+)/moderate (++)/severe (+++) (D), haplotype mild (+) vs. 
moderate (++)/severe (+++) (E) and moderate (++) vs. severe (+++) 
(F). Sensitivity analyses were carried out to investigate the influence of 
any one study on the overall meta‑analysis by sequential omission of indi‑
vidual studies. Figure S4. Forest plot of the meta‑analysis performed to 
investigate the association between ITPA rs6051702 polymorphisms and 
hemoglobin decline, included in the Hwang, et al. Article (32). Abbrevia‑
tions: CI, confidence intervals; OR, odds ratio. Figure S5. Sensitivity analy‑
sis for studies included in the meta‑analysis for severe anemia: rs1127354 
(A), haplotype absent (‑) vs. mild (+)/moderate (++)/severe (+++) (B) 
and haplotype mild (+) vs. moderate (++)/severe (+++) (C). Sensitivity 
analyses were carried out to investigate the influence of any one study 
on the overall meta‑analysis by sequential omission of individual studies. 
Figure S6. Sensitivity analysis for studies included in the meta‑analysis 
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